Evogene (NASDAQ: EVGN)

Отрасль

Защита растений, Семена и генетика

Темы

Химические средства защиты растений и удобрения, Гибридные семена и селекция, ГМ-признаки и редактирование генома

Роль

Не определена

Почему это биоэкономика

Evogene — вычислительная биология и химия: на собственной ИИ-платформе ChemPass AI ищет и оптимизирует малые молекулы для фармацевтики и сельского хозяйства.

Пока не указана поставщиком в решениях с доказательствами.

Дочерние компании: AgPlenus Ltd. · Biomica Ltd. · Casterra Ag Ltd. · Lavie Bio Ltd.

• 2026-03 Последний статус: 30 марта 2026 г. компания получила уведомление Nasdaq о несоответствии требованию к минимальной цене акций; срок на устранение продлён до 29 марта 2027 г. ↗ ↗ ↗
• 2026-07-08 Evogene and Tel Aviv University’s Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery - Evogene
  Evogene is expanding its AI-driven small-molecule drug discovery capabilities through a strategic collaboration with Tel Aviv University’s Blavatnik Center for Drug Discovery to accelerate translational work from Israeli academia, using its ChemPass AI™ …
• 2026-08-31 Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward
  Evogene is defending its recent strategic transformation, arguing that its focus on ChemPass AI, six external drug-development agreements, and significant cost reductions have already strengthened its financials and moved the company toward a more …
• 2026-09-30 Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance
  Evogene has received a Nasdaq extension, giving it an additional 180 days (to March 29, 2027) to regain the minimum $1.00 bid price, with continued trading on Nasdaq during the period; if it fails to meet the threshold for 10 consecutive days, it could be …
• 2026-08-18 Evogene Reports Second Quarter and First Half 2026 Financial Results
  Evogene is undergoing a strategic, AI-driven transformation into a lean computational chemistry company focused on generative design of small molecules for pharma and agricultural products, with expanding collaborations and a larger virtual chemical space …
• 2026-07-22 Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases - Evogene
  Evogene is partnering with ELEO Inc. to use its ChemPass AI platform for designing and optimizing oral small-molecule inhibitors of the PCSK9 pathway, aiming to accelerate discovery for hyperlipidemia and cardiovascular disease. The collaboration combines …
• 2026-06-24 Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization - Evogene
  Evogene announces a major milestone with Google Cloud advancing its ChemPass AI platform toward more autonomous small-molecule discovery and optimization, enabling earlier, richer target profiling and prioritization of high-potential candidates to accelerate …

Владельцы и инвесторы 6

Партнёры и сделки 2

Похожие компании

Kentegra Biotechnology Holdings LLC · Agriventure Egypt · Nawah Scientific · AgriEdge · DeepLeaf · Devgen · Bayer Crop Science Maghreb · Pathorec